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ARDS  Acute respiratory distress syndrome 
ALI  Acute lung injury 
AM  Alveolar macrophage 
BAL   Bronchoalveolar lavage 
BALF  Bronchoalveolar lavage fluid 
BE  Base excess in plasma 
ELISA  Enzyme-linked immunosorbent assay 
FiO2  Fraction of inspired oxygen 
hi-aft group  The group of inhalation of 5.0µg IL-10 after LPS injection 
hi-bef group  The group of inhalation of 5.0µg IL-10 before LPS injection 
HCO3
-  Plasma bicarbonate concentration 
HR  Heart rate 
IQR  Interquartile range 
IFN-γ  Interferon-gamma 
IL-1ß  Interleukin-1 beta 
IL-10  Interleukin-10 
IL-1ra  IL-1-receptor antagonist 
IL-6  Interleukin-6 
IL-8  Interleukin-8 
LPS  Lipopolysaccharide  
I:E   Ratio of inspiration time to expiration time 
iNOS  Inducible nitric oxide synthase 
kg   Kilogram 
lo-aft group  The group of inhalation of 0.5µg IL-10 after LPS injection lo-bef group  The group of inhalation of 0.5µg IL-10 before LPS injection 
MAP  Mean arterial blood pressure 
MMAD  Mass median aerodynamic diameter  
Mea  Measurement-time point during the experimental protocol 
mEq  Milliequivalent 
mEq/l  Milliequivalent per litre 
mRNA  Messenger-RNA 
NK  Natural killer cell 
PaCO2  Arterial carbon dioxide tension 
PaO2  Arterial oxygen tension 
PBS  Phosphate buffered saline 
PEEP  Positive end expiratory pressure 
pH  The logarithm of the reciprocal of hydrogen-ion concentration in gram atoms per litre 
Pmax  Peak airway pressure 
rhIL-10  Recombinant human IL-10  
Semi-IQR  Semi interquartile range 
TNF-α  Tumour necrosis factor-alpha 
vs.  Versus 
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1.  INTRODUCTION 
1.1.  Definition and Epidemiology of Acute Respiratory Distress Syndrome (ARDS) 
The acute respiratory distress syndrome (ARDS) is a clinical syndrome of acute lung 
inflammatory injury which was first described in 1967 by Ashbaugh with the following 
symptoms:  acute  respiratory  failure  refractory  to  oxygen  therapy,  decreased  lung 
compliance, and diffuse bilateral alveolar infiltration on the chest x-ray [3].   
In  1994,  the  American-European  Consensus  Conference  defined  criteria  for  the 
diagnosis of ARDS and acute lung injury (ALI), a less severe form of acute respiratory 
failure. The common criteria for ALI and ARDS include acute onset, bilateral infiltrates 
on  chest  x-ray,  and  no  clinical  evidence  of  increased  left  atrial  pressure  with  a 
pulmonary artery wedge pressure ≤ 18 mmHg [7]. While ALI is defined with a quotient 
of arterial oxygen tension (PaO2) and fraction of inspired oxygen (FiO2) ratio between 
200 and 300 mmHg, ARDS is defined by a more severe oxygenation failure with the 
PaO2/FiO2 ratio < 200 mmHg [7].  
Based on that definition, the incidence of ARDS is reported from 23 to 59 cases per 
100000 citizens in Europe and the United States, respectively [48] [62]. 
1.2.  Etiology and Pathophysiology of ARDS 
1.2.1.  Etiology of ARDS 
ARDS  arises  either  as  a  complication  of  a  direct  insult  to  the  lung  (pneumonia  or 
aspiration of gastric contents) or indirectly, when systemic inflammation reaches the 
lung which can be the case during clinical sepsis, severe trauma, or following massive 
transfusion. The leading risk factor for the development of ALI and ARDS is the sepsis 
syndrome,  which  is  responsible  for  up  to  40%  of  ARDS  cases  [1]  [35].  Although 
several progresses have been made in supportive care, the mortality arising from ARDS   2 
still ranges high from 35 to 40 percent [62]. Thus, alternative therapeutical strategies in 
ARDS-treatment  are  in  the  focus  of  clinical  and  experimental  research  to  possibly 
improve the prognosis of ARDS. 
1.2.2. Pathophysiology of ARDS 
ARDS  is  characterized  by  widespread  injury  of  structures  of  the  alveolar  capillary 
membrane,  which  causes  a  loss  of  epithelial  integrity  and  disruption  of  junctions 
between alveolar and endothelial cells. This results in increased pulmonary capillary 
permeability and flooding of the alveolar spaces with protein-rich fluid containing large 
number of  immunocompetent cell  populations among them neutrophils  and alveolar 
macrophages [78].  
In  the  acute  phase  of  ARDS,  activated  alveolar  macrophages  secret  proinflammatory 
cytokines  that  locally  stimulate  chemotaxis  and  activation  of  neutrophils.  Activated 
neutrophils adhere to the injured capillary endothelial cells and marginate through the 
interstitium  into  the  air  space.  Subsequently,  they  liberate  other  proinflammatory 
mediators  among  them  oxidants,  proteases,  and  leukotriens  thus  contributing  for  the 
aggravation of lung injury [78].  
There  is  evidence  that  the  intrapulmonary  origin  of  proinflammatory  cytokines  in 
ARDS plays an important role for the initiation and perpetuation of the inflammatory 
processes  within  the  lung.  Alveolar  macrophages  from  ARDS-patients  express 
proinflammatory  cytokines,  emphasizing  their  intrapulmonary  origin  [40]. 
Proinflammatory cytokine levels have been found increased in bronchoalveolar lavage 
fluid (BALF) of patients at risk for and with sustained ARDS as compared to nonseptic 
control patients [18] [70].    3 
The overwhelmed and sustained proinflammatory condition contributes to the poor prognosis 
in ARDS patients. Meduri et al. in 1995 reported that, at the onset of ARDS, the nonsurvivors 
had significantly higher levels of proinflammatory cytokines like TNF-α, IL-1ß, and IL-6 in 
plasma and in bronchoalveolar lavage fluid. In contrast, in survivors initial lower levels of 
these proinflammatory cytokines have been found [51] [52].  
Based on the results of the aforementioned studies [51] [52], the question arises if 
anti-inflammatory  therapies  aiming  the  overwhelming  inflammation  may  help  to 
improve the outcome in ARDS patients.  
1.3. Anti-inflammatory Therapy and ARDS 
Several clinical studies which directed toward neutralizing proinflammatory cytokines 
in ARDS induced by sepsis (like the administration of interleukin-1 receptor antagonist 
and soluble tumor necrosis factor receptor) did not show any significant improvement in 
the outcome from ARDS patients [23] [24].   
1.3.1. Interleukin-10 and ARDS 
There is evidence that low concentration of interleukin-10 (IL-10), an anti-inflammatory 
cytokine, is related closely to the incidence of ARDS [2] and the mortality rate of 
ARDS patients [17]. In addition, kinetics of IL-10 synthesis during the acute phase of 
ARDS  showed  that  IL-10  appeared  later  (7h  after  activation  of  monocytes  by 
lipopolysaccharide) in lower concentration than proinflammatory cytokines (4h after 
activation of monocytes by lipopolysaccharide) [13] [50].  
Based on these findings, the supplementation of IL-10 may be a promising approach for 
ARDS patients. Thus far, there is only one clinical report concerning the application of 
IL-10 during ARDS [6]. Bernard et al. in 1999 reported that lower proinflammatory   4 
cytokine  levels  and  a  trend  towards  reduced  duration  of  mechanical  ventilation  in 
ARDS patients who received intravenous injection of IL-10 [6].  
Interleukin-10 is mainly produced by T lymphocytes, B lymphocytes, monocytes, and 
macrophages  [14]  [55]  [63]  [76].  Functionally,  IL-10  inhibits  the  synthesis  of 
proinflammatory  cytokines  (like  TNF-α,  IL-1ß,  IL-6,  and  IL-8)  [20]  [47]  and  the 
formation of reactive nitrogen species in activated macrophages or monocytes in vitro 
[11].  Interleukin-10  also  suppresses  the  synthesis  of  interferon  gamma  (IFN-γ)  by 
helper T cells [21] and natural killer cells (NK) [34].  
Moreover, IL-10 enhances the release of anti-inflammatory mediators such as interleukin-
1 receptor antagonist (IL-1ra) [72] and soluble tumor necrosis factor receptor [15] by 
activated monocytes. Based on its anti-inflammatory properties, it was hypothesized that 
IL-10 administration may be useful in experimental sepsis [33]. Ge’rard et al. in 1993 
reported  that  tumor  necrosis  factor  (TNF)  serum  levels  of  mice  that  received 
intraperitonealy  IL-10  (1000U)  30min  before  intravenous  injection  of  100µg 
lipopolysaccharide (LPS) were significantly reduced and all animals survived [28].  
Related to supplementation of IL-10 in models of experimental endotoxemia, the route of 
administration  is  of  special  interest,  specifically  for  the  therapy  of  pulmonary 
inflammation.  Usually,  IL-10  has  been  administered  intravenously  [41]  [42]  [57]. 
Regarding  the  therapy  of  pulmonary  inflammation,  Inoue  in  1999  demonstrated  that, 
when  LPS  (12mg/kg)  and  IL-10  (20  or  40µg/kg)  were  simultaneously  intravenously 
injected, TNF-α production and neutrophil activation were inhibited thus leading to a 
significant reduction of inflammatory change in lung tissue [36].     
Taking into account the pathogenesis of ARDS which is closely related to cytokines 
synthesized in the lungs, IL-10 administration via the inhalational route in the treatment   5 
for  ARDS  may  be  more  attractive.  Local  administered  IL-10  preferably  would  act 
within lungs which is the site of inflammation as well as production of proinflammatory 
mediators. At the same time, local administered IL-10 may limit the systemic side-
effects of IL-10. In a previous study, our group could demonstrate that the levels of the 
proinflammatory  cytokines  TNF-α,  IL-1ß,  IL-6,  and  IFN-γ  in  plasma  and 
bronchoalveolar  lavage  fluid  were  significantly  reduced  by  inhaled  IL-10  in 
endotoxemic rats [31].  
In that study, IL-10 was administered prior to induction of experimental endotoxemia 
(LPS  5mg/kg),  at  a  median  dose  of  0.19µg  per  animal [31].  The  question  arises if 
inhaled IL-10 is also effective when it is inhaled during already existing endotoxemia 
and, further, if its effects are dose-dependent, specifically, if equipotent effect could be 
achieved with a much less dosage of IL-10. The present study was performed to clarify 
these questions. 
1.4. Objective 
In the present study, we aimed to determine if inhaled IL-10 either prior to or following 
to the intravenous injection of LPS (5mg/kg) at two doses (5.0µg or 0.5µg) will: 
Reduce the concentrations of proinflammatory cytokine TNF-α, IL-1ß, IL-6, and IFN-γ 
in plasma and bronchoalveolar lavage fluid (BALF) from endotoxemic animals.  
Reduce the concentration of nitrite release from ex vivo cultured alveolar macrophages 
from endotoxemic animals.   6 
2. MATERIALS and METHODS 
2.1. Animals  
The study was approved by the local board for the care and use of animal subjects, 
Darmstadt,  Germany  (decision  number  VI63-19c20/15-F91/31).  Experiments  were 
performed in 48 male Sprague-Dawley rats (Harlan Winkelmann, Borchen, Germany). 
Mean body weight of rats was 500 ± 33 g (mean ± standard deviation). Care of animals 
followed the “Guide for the Care and Use of Laboratory Animals” (National Academic 
Press, Washington D.C, 1996) enforced by local regulations.  
Experiments were conducted as a controlled, prospective, and randomized study and 
performed in the research centre of the faculty of medicine of the Johann-Wolfgang 
Goethe Frankfurt University,  Frankfurt am Main, Germany.  
2.2. Anaesthesia and Surgical Preparation  
Induction  of  anaesthesia  in  rats  was  performed  by  intraperitoneal  injection  of 
pentobarbital  50mg/kg  (Narcoren®,  Merial,  Halbergmoss,  Germany)  and  fentanyl 
0.05mg/kg (Janssen-Cilag, Neuss, Germany).  After sufficient depth of anaesthesia, rats 
were weighted and placed supine on a heating pad to keep body temperature between 
37.0
0C  and  38.0
0C  throughout  the  experiment.  Body  temperature  was  continuously 
monitored with a rectal probe (Siemens Sirecust 404, Siemens, Erlangen, Germany). 
After tracheotomy, a 13-gauge cannula (Abbott, Wiesbaden, Germany) modified with a 
connector for paediatric endotracheal tube was inserted into the trachea. The tracheal 
leak was sealed by an external ligature encompassing the intubated trachea. Thereafter, 
polythene catheters with inner and outer diameter of 0.58mm and 0.96mm, respectively, 
(SIMS  Portex,  Hythe,  UK)  were  inserted  into  the  right  femoral  vein  and  artery. 
Physiologic saline (NaCl 0.9%, Delta Select, Pfullingen, Germany) was intravenously   7 
infused  with  the  rate  of  12ml/kg/h.  Pentobarbital  and  fentanyl  were  intravenously 
infused with the rate of 5–10mg/kg/h and 2.5–5µg/kg/h, respectively. Heart rate and 
arterial blood pressure were continuously monitored by an electromechanical pressure 
transducer  (Statham  physiological  pressure  transducer  P23x1-1,  Viggo-Spectramed, 
Oxnard, CA, USA). Parameters were continuously displayed on a monitor (Siemens 
Sirecust 404, Siemens, Erlangen, Germany).  
When  mean  arterial  blood  pressure  decreased  below  80mmHg,  a  10%  hetastarch 
solution (HES, 200/0.5, 10%, B.Braun Melsungen, Melsungen, Germany) and natrium 
chloride  0.9%  (B.Braun  Melsungen,  Melsungen,  Germany)  in  1:1  mixture  was 
administered  as  bolus  injections.  When  hypotension  did  not  improve  following  two 
boluses, norepinephrine (Arterenol®, Aventis, Frankfurt, Germany) was infused at 0.02 
–  1mg/kg/h.  Blood  gas  analysis  was  performed  hourly  (ABL  500  Radiometer, 
Frankfurt, Germany). If metabolic acidosis occurred (pH < 7.30, BE < -5mEq/l, no 
respiratory components), a natriumbicarbonat solution 8.4% (NaHCO3 8.4%, B.Braun 
Melsungen,  Melsungen,  Germany)  was  intravenously  injected.  The  dose  of  
natriumbicarbonat solution 8.4% was calculated according to the following formula:  
NaHCO3
 
[mEq]= BE [mEq/l] x 0.3 x body weight [kg] 
BE: Base excess in plasma; mEq: Milliequivalent; mEq/l: Milliequivalent per litre; kg: 
Kilogram. 
Completion  of  surgical  preparation  was  followed  by  a  stabilization  period  of  15 
minutes.   8 
2.3. Mechanical Ventilation  
Rats were mechanically ventilated using pressure controlled ventilation by an infant 
ventilator  (Stephanie
®,  Stephan,  Gackenbach,  Germany).  Respiratory  settings  were:  
peak airway pressure (Pmax) 1.6kPa; positive end-expiratory pressure (PEEP) 0.4kPa; 
respiratory rate 30/min; fraction of inspired oxygen (FiO2) 0.21, ratio of inspiration time 
to expiration time (I:E) 1:2.   
2.4. Nebulisation 
For the period of nebulisation, rats were connected to a specifically designed nebuliser 
system, which was constructed and characterized by our group in a previous study, that 
was performed at the University Hospital of Munich [32]. Briefly, the system includes a 
ventilator (Siemens Servo
® 900 B, Siemens, Elema, Solna, Sweden) with a nebuliser 
unit  (Siemens  Nebuliser  945
®,  Siemens,  Elema,  Solna,  Sweden)  and  a  nebuliser 
chamber (Micro Cirrus
®, Intersurgical, St.Augstin, Germany).  
 
Figure 1. Schematic illustration of the nebuliser system. 1, Servo Ventilator (Siemens 
Servo  900  B);  2,  gas  supply;  3,  supply  pressure-reducing  valve;  4,  nebuliser  unit 
(Siemens nebuliser 945); 5, nebuliser chamber (Micro Cirrus); 6, T-piece; 7, expiratory   9 
line; 8, valve for control of peak airway pressure; 9, endotracheal tube; 10, monitor for 
peak airway pressure. 
For the period of aerosolisation, the nebuliser settings were: peak airway pressure (Pmax) 
1.5kPa, respiratory rate 40/min, FiO2 0.5. The nebuliser system generates and delivers 
aerosol during inspiration. Evaluation of resulting droplet size of the nebuliser system, 
effectiveness in aerosol delivery and animal compliance was previously published [32]. 
The generated particles have a mass median aerodynamic diameter of 2µm which is 
effective for alveolar deposition in intubated ventilated rats. Particle deposition fraction 
was 3.8%(1.3%) of the delivered dose (median [interquartile range]) [32].  
 
Figure 2. Description of aerosol. Cumulative particle fraction of the dried 
99mTc-labeled 
salt  particles  as  a  function  of  their  aerodynamic  diameter  measured  by  the  aerosol 
centrifuge.    10 
 
Figure  3.  Detection  of  deposited  intrapulmonary  fluorescent  microspheres. 
Fluorescence microscopy of liquid nitrogen-fixed pulmonary tissue of the right middle 
lobe  of  a  rat  exposed  to  aerosolized  microspheres  for  40min  (magnification  200x  ; 
gauge: 20µm)   11 
2.5. Experimental Protocol of the Present Study 
After  surgical  preparation  and  a  stabilization  period  of  15  minutes,  animals  were 
randomly assigned to six groups (n = 8, each).  
2.5.1. Preparation of LPS 
LPS  was  prepared  from  Escherichia  coli  055:B5  (Sigma-Aldrich,  Deisenhofen, 
Germany), diluted in phosphate buffered saline (PBS) (Serva, Heidelberg, Germany).  
2.5.2. Preparation of Interleukin-10 
Recombinant murine interleukin-10 (R&D Systems, Wiesbaden, Germany) as a sterile 
powder, purity > 98%, specific activity 5 x 10
5U/mg, was reconstituted in PBS to two 
final concentrations (5.0µg/ml or 0.5µg/ml) and stored in aliquots of 1ml at -80
0C.   
2.5.3. Protocol of Experiments  
(1) Sham group: Animals received 1ml nebulised PBS (the solvent of IL-10 used in the 
other groups) within 40 minutes before 1ml intravenous injection of saline (placebo), 
which was the solvent of LPS used in the other groups.  
(2) LPS-only group: Animals received intravenous injection of LPS 5.0mg/kg and no 
further intervention. 
(3)  hi-bef  group:  Animals  received  nebulised  IL-10  at  5.0µg  (1ml,  5.0µg/ml, 
corresponding to 0.19µg/rat) within 40 minutes before intravenous injection of LPS 
5.0mg/kg.  
(4) lo-bef group: Animals received nebulised  IL-10 at 0.5µg (1ml, 0.5µg/ml, corresponding 
to 0.019µg/rat) within 40 minutes before intravenous injection of LPS 5.0mg/kg. 
(5) hi-aft group: Animals received nebulised IL-10 at 5.0µg (1ml, 5.0µg/ml, corresponding 
to 0.19µg/rat) within 40 minutes after intravenous injection of LPS 5.0mg/kg.   12 
(6) lo-aft group: Animals received nebulised IL-10 at 0.5µg (1ml, 0.5µg/ml, corresponding 
to 0.019µg/rat) within 40 minutes after intravenous injection of LPS 5.0mg/kg. 
Haemodynamic and respiratory parameters were continuously monitored with hourly 
performed blood gas analyses as described above. At the end of the observation period 
(after 4 hours of endotoxemia or saline injection, respectively), animals were sacrificed 
by exsanguination via the femoral artery catheter. A thoracotomy was performed and 
lungs were immobilized for bronchoalveolar lavage. 
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  Figure 4. Schematic illustration of the characterization of six groups. 
Mea1,  Mea2,  Mea3,  Mea4,  and  Mea5:  are  the  first,  second,  third,  fourth,  and  fifth  time  point  of 
measurement  of  heart  rate,  arterial  blood  pressure,  and  arterial  blood  gas  analysis  after  preparation 
(Mea1)  and  one,  two,  three,  and  four  hours  following  the  injection  of  LPS  or  saline  (Mea2-5), 
respectively. 
 
  Group 4   13 
2.6.  Bronchoalveolar Lavage, Isolation, and Culture of Alveolar Macrophages  
Lungs were rinsed with sterile PBS through the tracheal cannula with ten aliquots of 
10ml sterile PBS. Every rinse with a 10ml aliquot was performed within 30 seconds, 
and  then  bronchoalveolar  lavage  fluid  was  gently  aspirated  within  30  seconds. 
Recovered fluid of the first aliquot was collected in a 50ml conical tube and that of the 
nine remaining aliquots was pooled in other 50ml conical tubes. 
The 50ml conical tubes containing bronchoalveolar lavage (BAL) were centrifuged at 
1500rpm for 10min. The supernatant of the first aliquot of BAL was stored at -80
0C for 
further analysis. The cell pellet of the first aliquot was pooled with the cell pellet of the 
remaining nine aliquots of BAL, then washed twice with PBS and resuspended in RPMI 
1640 culture medium supplemented with 100U/ml penicillin, 100µg/ml streptomycin 
and 10% fetal bovine serum (Gibco-BRL, Eggenstein, Germany). Total number of cells 
was assessed with a haemocytometer (Coulter, Krefeld, Germany). After staining with 
May-Gruenwald-Giemsa,  cellular  populations  were  identified  by  using  air-dried 
cytocentrifuge  smears  (500rpm  x  5min)  and  the  fraction  of  mononuclear  cells  was 
determined  by  morphologic  criteria.  Cell  viability  was  determined  by  trypan  blue 
method  (1%  trypan  blue  solution,  Fluka,  Neu  Ulm,  Germany).  Ten  micro  litres  of 
trypan blue solution was added to 20µl of cell suspension, and then the number of 
unstained cells was counted under a microscope. Viable cells do not take up the trypan 
blue stain. The percentage of viable cells was calculated by dividing the number of 
unstained cells by the total number of cells, multiplied by 100. Cells were plated in 24-
well polystyrene plates (Nuclon Delta Surface, Nunc, Roskilde, Denmark) at 0.2 × 10
6 
vital cells/well. After cultivation for 2h (37°C, 5% CO2, 21% O2), cells were washed 
and  non-adherent  cells  were  removed.  Adherent  cells  were  regarded  as  alveolar   14 
macrophages. Alveolar macrophages were cultured with 0.5ml of the aforementioned 
culture-medium for 24h except for alveolar macrophages of  two wells stimulated with 
LPS (5µl/well; 10µg/ml) just prior to the culture. 
2.7.  Processing of Plasma Samples   
The blood samples were centrifuged at 5000rpm for 5min. The resulting plasma was 
collected and frozen at -80
0C until further analysis.  
2.8.  Nitrite Assay 
After 24 hours of the culture of alveolar macrophages, culture supernatant was collected 
and centrifuged at 2000rpm for 10min. Nitric oxide release from alveolar macrophages 
was determined by evaluating the accumulation of their oxidation product nitrite in cell-
free supernatants with the Griess reaction [16]. Fifty micro litres of the supernatant were 
mixed with 50µl of Griess reagent (Merck, Darmstadt, Germany) (1% sulphanilamide, 
0.1%  N-1-naphtylethylenediamine,  and  2.5%  phosphoric  acid).  After  ten-minute 
incubation at room temperature, the absorbance of the reaction product was measured at 
550nm with  a micro  plate reader  (Salzburger  Labortechnik,  Salzburg, Austria). The 
nitrite  concentration  in  culture  supernatants  was  determined  by  comparison  with  a 
nitrite standard curve.   
2.9.  Enzyme Linked Immunosorbent Assay 
Concentrations of TNF-α, IL-1ß, IL-6, IFN-γ, and IL-10 in BALF and plasma were 
determined  by  enzyme  linked  immunosorbent  assay  (ELISA;  R&D  Systems, 
Wiesbaden, Germany). These assays were implemented by the quantitative sandwich 
enzyme immunoassay technique. A monoclonal antibody (capture antibody) specific for 
a  determined  cytokine  was  pre-coated  onto  a  micro  plate.  Standards,  controls,  and 
samples were pipetted into the wells and any determined cytokine present was bound by   15 
the immobilized antibody. After washing, any unbound substances were removed. An 
enzyme-linked polyclonal antibody (detection antibody) specific for each cytokine was 
added to the wells. After incubation and washing substrate solution was added to the 
wells.  The  enzyme  reaction  yielded  a  blue  product  that  turned  yellow  when  Stop 
solution  was  added.  Colour  intensity  was  measured  in  proportion  to  the  amount  of 
cytokine bound in the initial step. Cytokine concentration in pg/ml was then determined 
on the basis of the standard curve.     
2.10.  Statistics 
Data were expressed as median (semi-interquartile range, semi-IQR). Statistical analysis 
was  performed  with  the  SigmaStat
®  software  package  (version  2.0,  SPSS-Jandel 
Scientific, Erkrath, Germany).  
Haemodynamic and arterial blood gas parameters at time points Mea1 and Mea5 within 
each group were compared by the Signed Rank Test.  
Haemodynamic and arterial blood gas parameters of groups receiving IL-10 aerosol 
were compared to those of the LPS-only group at the time points Mea1 and Mea5, 
respectively, by the multisample test – the Rank Sum Test with Bonferroni Correction.  
Similarly, nitric oxide release from cultured alveolar macrophages, total numbers of 
alveolar macrophages and the number of vital alveolar macrophages in BAL, cytokine 
concentrations  in  BALF  and  in  plasma  of  groups  receiving  IL-10  aerosol  were 
compared to those of the LPS-only group by the multisample test - the Rank Sum Test 
with Bonferroni Correction.  
Differences in the aforementioned parameters compared by the multisample test- the 
Rank  Sum  Test  with  Bonferroni  Correction  and  by  the  Signed  Rank  Test  were 
considered significant at  p< 0.0125 and p< 0.05, respectively.    16 
3. RESULTS 
3.1. Haemodynamics 
Haemodynamic parameters in this study including mean arterial blood pressure (MAP) 
and heart rate (HR) were measured after preparation, then hourly until termination of 
experimental  protocol  after  4h  at  induction  of  experimental  endotoxemia  or  saline 
injection. Results of haemodynamic parameters are shown in Figure 5 and 6.  
There were no statistically significant differences in mean arterial blood pressure and 
heart rate when groups receiving IL-10 aerosol were compared to the LPS-only group at 
Mea1 and Mea5, respectively. Similarly, there were no statistically significant differences 
in the aforementioned parameters at Mea1 versus Mea5 within each group.  
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Figure 5. MAP at the time points after preparation and then hourly until termination of 
the experimental protocol after 4h of endotoxemia or saline injection. Data as median 
(semi-IQR). 
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Figure 6. HR at the time points after preparation and then hourly until termination of 
the experimental protocol after 4h of endotoxemia or saline injection. Data as median 
(semi-IQR). 
3.2. Arterial Blood Gas Analysis  
Results  of  arterial  blood  gas  analysis  are  shown  in  Figures  7  to  11.  There  were  no 
statistically significant differences in PaO2, PaCO2, pH, HCO3
- concentration, and BE when 
groups receiving IL-10 aerosol were compared to the LPS-only group at Mea1 and Mea5, 
respectively.  Similarly,  there  were  no  statistically  significant  differences  in  the 
aforementioned parameters at Mea1 versus Mea5 within each group.  
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Figure 7. PaO2 at the time points after preparation and then hourly until termination of 
the experimental protocol after 4h of endotoxemia or saline injection. Data as median 
(semi-IQR). 
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Figure 8. PaCO2 at the time points after preparation and then hourly until termination of 
the experimental protocol after 4h of endotoxemia or saline injection. Data as median 
(semi-IQR). 
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Figure 9. pH at the time points after preparation and then hourly until termination of the 
experimental  protocol  after  4h  of  endotoxemia  or  saline  injection.  Data  as  median 
(semi-IQR). 
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Figure 10. HCO3
- concentration at the time points after preparation and then hourly 
until  termination  of  the  experimental  protocol  after  4h  of  endotoxemia  or  saline 
injection. Data as median (semi-IQR). 
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Figure 11. BE at the time points after preparation and then hourly until termination of 
the experimental protocol after 4h of endotoxemia or saline injection. Data as median 
(semi-IQR). 
3.3.  Alveolar  Macrophages  and  Nitrite  Release  from  cultured  Alveolar 
Macrophages  
Total  number  of  alveolar  macrophages  (AMs)  and  the  number  of  vital  AMs  in 
bronchoalveolar lavage (BAL) are presented in table 1.   
When compared to the LPS-only group, total number of AMs in BAL of the hi-bef group 
was significantly increased by 88% (2.6(0.6)x10
6/ml vs. 4.9(0.9)x10
6/ml) (p< 0.0125) and 
the number of vital AMs in BAL of the hi-bef group was significantly increased by 92% 
(2.5(0.6)x10
6/ml vs. 4.8(0.9)x10
6/ml) (p< 0.0125).  
There  were  no  statistically  significant  differences  in  total  number  of  AMs  and  the 
number of vital AMs in BAL, when the lo-bef, the hi-aft, and the lo-aft groups were 
compared to the LPS-only group.  
Table 1. Characteristics of alveolar macrophages in the bronchoalveolar lavage.  
  Sham  
group 
LPS-only 
group 
hi-bef  
group 
lo-bef  
group 
hi-aft 
 group 
lo-aft  
group 
Total AMs  
in BAL 
(x10
6/ml) 
3.9 (0.8)  2.6 (0.6)  4.9 (0.9)*  2.9 (0.2)  3.0 (1.0)  2.8 (0.9) 
Vital AMs  
in BAL  
(x10
6/ml)  
3.8 (0.8)  2.5 (0.6)  4.8 (0.9)*  2.8 (0.2)  2.8 (0.9)  2.7 (0.9) 
Data as median (semi-IQR); * hi-bef group vs. LPS-only group (p< 0.0125). 
Spontaneous release of nitrite from ex-vivo cultured alveolar macrophages within 24h is 
displayed in Figure 12.  When compared to the LPS-only group, nitrite release of the hi-  22 
bef  group  was  significantly  reduced  by  69.3%  (17.6(18.7)nmol/24h  vs. 
5.4(4.6)nmol/24h)  (p<  0.0125).  There  were  no statistically  significant  differences  in 
spontaneous release of nitrite, when the lo-bef, the hi-aft, and the lo-aft groups were 
compared to the LPS-only group.  
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Figure 12.  Spontaneous release of nitrite from ex-vivo cultured alveolar macrophages 
within 24h. Data as median (semi-IQR); * hi-bef group vs. LPS-only group (p< 0.0125).  
 3.4. Cytokine concentrations  in BALF 
Measured proinflammatory and anti-inflammatory cytokine concentrations in BALF are 
displayed in Figures 13 to 17.  
There  were  no  statistically  significant  differences  in  TNF-α,  IL-1ß,  and  IL-6 
concentrations in BALF when groups receiving IL-10 aerosol were compared to the 
LPS-only  group.  However,  IFN-γ  concentrations  in  BALF  from  the  hi-bef 
(32(26)pg/ml),  the  hi-aft  (75(26)pg/ml),  the  lo-bef  (17(27)pg/ml),  and  the  lo-aft 
     Sham       LPS-only     hi-bef          lo-bef         hi-aft          lo-aft          
*   23 
(55(54)pg/ml)  groups  were  significantly  higher  than  that  from  the  LPS-only  group 
(0(0)pg/ml) (p< 0.0125).  
In the present study, IL-10 was detectable in all BALF samples except for one sample 
from the LPS-only group. As compared to the LPS-only group, IL-10 concentration in 
BALF  from  the  hi-bef  group  was  2.5  fold  higher  (15(12)pg/ml  vs.  38(26)pg/ml) 
(p<0.0125).
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Figure 13. TNF-α concentrations in BALF. Data as median (semi-IQR) 
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Figure 14. IL-1ß concentrations in BALF. Data as median (semi-IQR). 
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Figure 15. IL-6 concentrations in BALF. Data as median (semi-IQR). 
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Figure 16. IFN-γ concentrations in BALF. Data as median (semi-IQR). * hi-bef group 
vs. LPS-only group; ~ lo-bef group vs. LPS-only group; # hi-aft group vs. LPS-only 
group; § lo-aft group vs. LPS-only group (p< 0.0125).  
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Figure 17. IL-10 concentrations in BALF. Data as median (semi-IQR); * hi-bef group 
vs. LPS-only group (p< 0.0125). 
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3.5. Cytokine concentrations in Plasma 
Measured proinflammatory and anti-inflammatory cytokine concentrations in plasma 
are displayed in Figures 18 to 22.   
The  TNF-α,  IL-1ß,  and  IL-6  concentrations  in  plasma  from  the  hi-bef  group  were 
significantly reduced as compared to the LPS-only group (p< 0.0125). There were no 
statistically  significant  differences  in  the  TNF-α,  IL-1ß,  and  IL-6  concentrations  in 
plasma, when the hi-aft, the  lo-bef, and the lo-aft groups were compared to the LPS-
only group. 
Specifically, TNF-α concentration in plasma from the hi-bef group was significantly 
reduced  by  62.5%  as  compared  to  the  LPS-only  group  (262(69)pg/ml  vs. 
700(203)pg/ml) (p< 0.0125). IL-1ß concentration in plasma from the hi-bef group was 
significantly reduced by 72.8% as compared to the LPS-only group (254(326)pg/ml vs. 
936(212)pg/ml) (p< 0.0125). IL-6 concentration in plasma from the hi-bef group was 
significantly  reduced  by  24.8%  as  compared  to  the  LPS-only  group  
(51722(60105)pg/ml vs. 68815(26457)pg/ml) (p< 0.0125). 
IFN-γ  concentrations  in  plasma  from  the  hi-bef  (863(529)pg/ml),  the  lo-bef 
(908(392)pg/ml), and the lo-aft (1112(177)pg/ml) groups were significantly reduced by 
71.3%,  69.9%,  and  63.1%,  respectively  as  compared  to  the  LPS-only  group 
(3017(483)pg/ml) (p< 0.0125).  
IL-10  concentrations  in  plasma  from  groups  receiving  IL-10  aerosol  did  not  reach 
statistically significant differences as compared to the LPS-only group.    27 
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Figure 18. TNF-α concentrations in plasma. Data as median (semi-IQR); * hi-bef group vs. 
LPS-only group (p< 0.0125).  
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Figure 19. IL-1ß concentrations in plasma. Data as median (semi-IQR); * hi-bef group 
vs. LPS-only group (p< 0.0125).  
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Figure 20. IL-6 concentrations in plasma. Data as median (semi-IQR); * hi-bef group 
vs. LPS-only group (p< 0.0125).  
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Figure 21. IFN- γ concentrations in plasma. Data as median (semi-IQR); * hi-bef group 
vs. LPS-only group; ~ lo-bef group vs. LPS-only group; § lo-aft group vs. LPS-only 
group (p< 0.0125).  
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Figure 22. IL-10 concentrations in plasma. Data as median (semi-IQR). 
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4. DISCUSSION 
4.1. Methods 
4.1.1.  Aerosol Therapy 
In pulmonary diseases, direct delivery of drugs is attractive because of reduced dosage 
and less systemic side-effects. Aerosol production and delivery with specific nebulisers 
are the adequate and established method. 
ARDS  patients  usually  present  with  acute  severe  respiratory  failure  and  require 
endotracheal intubation with mechanical ventilation. Thus, in parallel to that clinical 
scenario,  we  performed  IL-10  inhalation  to  mechanically  ventilated  intubated 
anesthetized rats.  
Actually,  two  methods  are  commonly  applied  to  produce  aerosols  in  controlled 
ventilation:  the  use  of  ultrasonic  nebulisers  and  jet  nebulisers.  However,  ultrasonic 
nebulisers  produced  a  high  temperature  and  highly  energetic  vibrations  during 
operation.  Consequently,  the  risk  of  loss  of  biological  activity  of  proteins  such  as 
interferon  has  been  demonstrated  [37].  Moreover,  the  droplet  size  distribution  of 
ultrasonic nebulisers generally is significantly broader than that of jet nebulisers [61]. 
Thus, the implementation of a jet nebuliser was more reasonable for aerosol production 
and delivery from liquid formulation of IL-10 in the present study.  
The  mass  median  aerodynamic  diameter  (MMAD),  that  denotes  the  particle  size at 
which half of the total aerosol mass contains larger and half smaller particles, is an 
important  value  used  for  estimating  particles’  deposition  at  different  anatomic  sites 
within the respiratory tract.  
The  jet-nebuliser  system  generated  and  delivered  particles  with  MMAD  of 
approximately 2.0µm  in ventilated intubated rats. Deposition was found in terminal   31 
airways, indicating that aerosol reached the alveolar level [32]. This is consistent with 
Coleman’s  report  that  particles  2-5µm  in  MMAD  were  ideal  for  bronchoalveolar 
deposition [10].  
The effectiveness of aerosol therapy highly depends on the quantity of intrapulmonary 
drug deposition.  Even  if aerosolized particles are within a  sufficient range to reach 
terminal airways, only a small percentage of the nebulised dose is effectively deposited. 
In  mechanically  ventilated  patients,  intrapulmonary  delivery  fractions  have  been 
reported to be less than 3% [26] [73]. Our jet-nebuliser system could demonstrate in rats 
a deposition fraction of 3.8%(1.3%) (median [interquartile range]) of the nebulised dose 
located in alveoli and small airway thus indicating sufficient drug delivery. 
Moreover,  the  administration  of  our  jet-nebuliser  system  was  safe  in  ventilated 
intubated rats by the implementation of the continuously adjustable valve for control 
and adjustment of peak airway pressure at  1.5kPa during the nebulisation.  None of 
inhaled  rats  developed  detectable  acute  lung  injury  (barotrauma  and  volutrauma), 
indicated  by  the  absence  of  alterations  in  histologically  detectable  structural  tissue 
damage [32]. This is in line with results from Osier et al. in 1997 and Lizio et al. 2001, 
who found that peak airway pressure during aerosolisation reaching about 1.5kPa was 
safe in rats [46] [56].  
4.1.2. Experimental Endotoxemia 
Intravenous injection of LPS in animals is a commonly applied experimental method to 
mimic symptoms associated with systemic inflammatory response syndrome, human 
sepsis, and sepsis-induced ARDS, including pulmonary inflammation [38] [54].  
In contrast, intratracheal instillation or inhalation of LPS [19] [44], which are known to 
also induce acute pulmonary inflammation were not used as a model in the present   32 
study since these approaches do not mimic the most commonly seen pathophysiologic 
sequences  leading  to  acute  lung  injury  in  humans,  i.e.  the  systemic  inflammatory 
response syndrome and sepsis.  
4.2. Results  
4.2.1. Haemodynamics 
Haemodynamic changes were no main parameters of the study because the changes 
were influenced by fluid and vasopressor therapy to prevent the development of septic 
shock. Due to consequent therapy of hypotension, no mean arterial pressure lower than 
70mmHg  was  observed.  In  the  present  study,  we  found  that  the  differences  in 
haemodynamic parameters between groups receiving IL-10 aerosol and the LPS-only 
group at the same time point Mea1 or Mea5 have not been statically significant. Our 
findings were consistent with our previous study, which showed that inhalation of 5µg 
IL-10 before LPS injection (which corresponds to the hi-bef group of the present study) 
did not attenuate the hypotensive response to endotoxin [31]. There is an evidence that 
heart  rate  and  mean  arterial  blood  pressure  in  volunteers  who  received  intravenous 
injection  of  IL-10  (25µg/kg)  simultaneously  with  endotoxin  (4ng/kg)  were  not 
significantly different as compared to volunteers only received intravenous injection of 
endotoxin  [57].  In  contrast,  Kumar  et  al.  in  2005  reported  that  heart  rate  was 
significantly  lower at points between 6.5 and  8h after intravenous  injection of LPS 
(4ng/kg) in the intravenously injected IL-10 group (1, 10, and 25µg/kg) immediately 
before LPS injection as compared to the placebo group (which corresponds to the LPS-
only group of the present study) in human endotoxemic model [41]. Difference in heart 
rate between our result and Kumar’s result may be explained by different subjects (rats 
vs.  human  volunteers),  routes  of  IL-10  administration  (inhalation  vs.  intravenous   33 
injection), doses of IL-10 administration (5µg or 0.5µg vs. 1, 10, and 25µg/kg), doses of 
LPS injection (5mg/kg vs. 4ng/kg), and finally, different observation period after LPS 
injection (4h vs. 24h).  
4.2.2. Arterial Blood Gas Analysis 
Changes  of  acid-base  balance  were  no  main  parameters  in  the  study  because  if 
metabolic  acidosis  occurred,  natriumbicarbonat  solution  in  increments  was 
intravenously  injected  to  maintain  acid-base  homeostasis.  Moreover,  experimental 
animals were mechanically ventilated. Hence, results of hourly-performed arterial blood 
gas analysis were considerably influenced by the ventilatory regime which was adjusted 
to maintain normocapnia.  
In the present study, IL-10 inhalation did not improve hypoxemia and acidosis induced by 
endotoxemia. Our findings were consistent with our previous study which showed no 
significant differences in arterial oxygen tension when the LPS-only group was compared 
to the group of inhalation of 5µg IL-10 before LPS injection (which corresponds to the hi-
bef group of the present study) [31]. Similarly, Knoblach et al. in 1998 demonstrated that 
the arterial blood gas analysis was not affected by intravenous or subcutaneous injection 
of IL-10 (100µg) in a model of traumatic brain injury in rats [39]. 
4.2.3.  Alveolar  Macrophages  and  Nitrite  Release  from  cultured  Alveolar 
Macrophages 
The main targets of IL-10 are mononuclear cells and tissue macrophages which are a 
major  source  of  IL-10  production  in  vivo.  Macrophages  play  a  central  role  during 
inflammation, as they are also a target for pathogens and of importance for both, the 
activation  of  specific  and  innate  immune  response.  Alveolar  macrophages  serve  a   34 
regulatory role by releasing proinflammatory mediators, which can further increase the 
intensity of the inflammatory response.  
In  the  present  study,  LPS  injection  caused  a  decrease  in  the  quantity  of  alveolar 
macrophage  count  in  the  BAL  which  affirms  results  from  other  investigators  that 
showed  a  decrease  in  the  absolute  number  of  recoverable  alveolar  macrophages 
following infusion of endotoxin [9] [40] [65]. In contrast, Li et al. in 1998 found the 
number  of  alveolar  macrophages  only  reduced  one  hour  following  intratracheal 
instillation  of  LPS  as  compared  to  baseline  in  BAL,  while  thereafter  alveolar 
macrophage count started to rise over time of the ARDS course [44].  
In the present study, reduction of the number of alveolar macrophages in BAL after LPS 
injection was prevented by IL-10 aerosol. The total number and the vital number of 
alveolar macrophages in BAL from the hi-bef group was significantly higher than those 
from the LPS-only group (p< 0.0125). This result corresponds with our previous study 
which showed that the total number of alveolar macrophages in the group of inhalation 
of 5µg IL-10 before LPS injection (which corresponds to the hi-bef group of the present 
study) was significantly higher than in the LPS-only group [31]. In contrast, in a model 
of immune complex-induced alveolitis, Mulligan et al. in 1993 reported that the number 
of alveolar macrophages in BAL fell by 65% 4h after IL-10 instilled into the airways 
[53]. The reason for difference between our present finding and Mulligan’s result may 
be  based  on  different  experimental  models.  While  we  performed  LPS  intravenous 
injection, Mulligan et al. instilled Immunoglobulin (IgA and IgG) into the airway for the 
induction of lung injury. A further cause may be the different dosage of IL-10. Dosage of 
IL-10 in Mulligan’s experiment (25ng/rat) was lower than that in our present study 
(0.19µg/rat).    35 
The reason of the significant elevation of the total number and the vital number of 
alveolar macrophages in BAL from the hi-bef group as compared to the LPS-only group 
in our present study has been not explained completely. Bingisser et al. in 1996 found 
that LPS-induced apoptosis in alveolar macrophages was significantly reduced by the 
macrophage-deactivating cytokine IL-10 [8]. One may speculate that the LPS-induced 
apoptosis in alveolar macrophages, which declines after IL-10 administration resulted in 
significant elevation of the vital number of alveolar macrophages in the BAL in the hi-
bef group. Fuchs et al. in 1996 reported that there were significant elevations in the 
number  of  peripheral  blood  monocytes  (the  precursor  of  alveolar  macrophages)  in 
healthy volunteers after intravenous injection of a single bolus of IL-10 (1, 10, and 
25µg/kg)  [25].  It  may  be  possible  that  the  increased  number  of  peripheral  blood 
monocytes after IL-10 administration leads to a significant elevation of total number of 
alveolar macrophages in BAL in the hi-bef group. 
The  meaning  of  the  significant  elevation  of  total  number  and  the  vital  number  of 
alveolar macrophages in BAL from the hi-bef group as compared to the LPS-only group 
in  the  present  study  has  been  not  completely  elucidated.  Steinberg  et  al.  in  1994 
demonstrated that the number of alveolar macrophages in BAL increased in survivors 
from ARDS, both in absolute numbers and as a percentage of total cells [67]. 
Nitric  oxide  is  a  ubiquitous  messenger  molecule  that  affects  various  biological 
functions. The inducible nitric oxide synthase (iNOS) is responsible for the production 
of large amounts of nitric oxide, an important mediator of inflammation [66]. iNOS is 
expressed  from  macrophages,  epithelial  cells,  endothelial  cells  and  regulated  at  the 
pretranslational level [74]. LPS or proinflammatory cytokines (like IFN-γ, IL-1ß, and 
TNF-α) have been shown to induce iNOS expression [16] [69] [75]. Under physical   36 
conditions, nitric oxide is produced in low concentration and participates in cellular 
metabolism,  signal  transduction,  and  cellular  protection.  In  an  inflammatory 
environment, mononuclear cells increasingly release nitric oxide induced by iNOS [40] 
[44].  Nitric  oxide  binds  with  other  oxidants  (like  superoxide  anion)  generated  by 
inflammatory  cells,  thus  leading  to  the  formation  of  reactive  nitrogen  species  (like 
peroxynitrite) that are more reactive and toxic than nitric oxide itself [74]. Reactive 
nitrogen  species  exert  cytotoxic  effects  through  enzyme  inhibition,  toxic  radical 
formation,  inactivation of  metabolic  pathways,  damage  to  cell  structures  as  well  as 
proteins,  and  alteration  of  gene  expression  [45].  In  septic  shock,  nitric  oxide 
overproduction  is  responsible  for  vasodilatation  and  cardio  depression,  which 
contributes  to  haemodynamic  instability  and  tissue  damage  [30].  Therefore,  the 
prevention of excessive formation of nitric oxide in endotoxemia is of therapeutical 
interest. 
Interleukin-10  has  been  demonstrated  to  reduce  iNOS  expression  and  nitric  oxide 
production  by  mononuclear  cells.  Cunha  et  al.  in  1992  reported  that  maximum 
inhibition of nitric oxide synthesis by IL-10 was achieved when macrophage cells were 
preincubated  with  IL-10  18h  before  activation  with  IFN-γ  [11].  Thus,  IL-10  may 
contribute to reduce cytotoxic activity of nitric oxide [27].  
In the present study, nitrite release was measured in supernatants of ex-vivo cultured 
cells as an indicator for nitric oxide  production resulting from the induction of iNOS of 
alveolar macrophages.  Spontaneous release  of nitrite from ex-vivo  cultured alveolar 
macrophages in the hi-bef group was significantly lower than that in the LPS-only group 
(p<  0.0125).  This  finding  corresponds  with  our  previous  study,  which  showed  that 
inhalation of 5µg IL-10 before LPS injection (which corresponds to the hi-bef group of   37 
the  present  study)  suppressed  nitrite  release from  cultured alveolar  macrophages  by 
96%  as  compared  to  the  LPS-only  group  in  a  model  of  endotoxemic  rats  [31].  In 
contrast, Perretti et al. in 1995 reported that intravenous injection of IL-10 (1µg) 20min 
before intraperitoneal injection of LPS (0.3mg/kg) in mice did not cause the reduction 
in this LPS-stimulated nitric oxide production by peritoneal macrophages ex-vivo [60]. 
The difference in nitric oxide production between our present study and the study from 
Perretti et al. may be explained by different routes of LPS exposure (intravenous vs. 
intraperitoneal  injection),  doses  of  LPS  (5mg/kg  vs.  0.3mg/kg),  routes  of  IL-10 
administration (inhalation vs. intravenous injection), time points of IL-10 administration 
(40min vs. 20min before  LPS  injection), doses of  IL-10 (5µg  vs.  1µg), and finally 
different  sources  producing  nitric  oxide  (alveolar  macrophages  vs.  peritoneal 
macrophages). 
There is evidence that nitrite levels in BALF may play a certain role for the prognosis in 
sepsis patients. Sittipunkt et al. in 2001 reported that nitrite levels were significantly 
elevated in BALF from patients at risk and after the onset of ARDS, but were even 
more  significantly  elevated  in  nonsurvivors  than  survivors,  particularly  in  ARDS 
patients after sepsis [66].  
Taking into account the reduction of spontaneous nitrite release from ex-vivo cultured 
alveolar macrophages in the hi-bef group as compared to the LPS-only group in our 
present study, it can be reasoned that inhalation of 5µg IL-10 before LPS injection (the 
hi-bef group) appears to be more beneficial than inhalation of IL-10 following LPS 
injection in the present model.   38 
4.2.4. Cytokine concentrations  in BALF 
In the present study, we found that there were no statistically significant differences in 
proinflammatory cytokine TNF-α, IL-1ß, and IL-6 concentrations in BALF between 
groups receiving IL-10 aerosol and the LPS-only group. IFN-γ concentrations in BALF 
from groups receiving IL-10 aerosol were significantly increased as compared to the 
LPS-only  group  (p<  0.0125).  The  findings  implicate  that  IL-10  inhalation  with  any 
dosage (0.5µg or 5µg) and at any time point (before or after LPS injection) did not act 
anti-inflammatory  within  the  lungs  in  the  used  model.  There  is  evidence  that 
endbronchial administration  of  IL-10  has  been found  effective  in animal  models  of 
acute  pulmonary  inflammation.  Escofier  et  al.  in  1999  reported  that  intranasal 
administered IL-10 (0.1µg) inhibited TNF-α level in BALF of rats exposed to LPS-
aerosol [19]. In a previous study, our group could demonstrate that inhalation of 5µg IL-10 
before LPS injection (which corresponds to the hi-bef group of the present study) reduced 
levels of TNF-α, IL-1ß, IL-6, and IFN-γ in BALF in a comparable model of endotoxemic 
rats [31]. A reason for the different results between our studies may be explained by the 
fact that our observation period after LPS injection in the present study was shorter than 
that in the previous study (4h vs. 6h). Therefore, it may be speculated that we did not 
detect a significant suppression of proinflammatory cytokine concentrations in BALF 
from the hi-bef group in the present study due to kinetic reasons.  
In addition, IL-10 concentration in BALF from the hi-bef group was significantly higher 
than that from the LPS-only group (p< 0.0125) in the present study. In contrast, in a 
previous  study,  we  could  demonstrate  that  there  was  no  statistically  significant 
difference in IL-10 level in BALF between the group of inhalation of 5µg IL-10 before 
LPS injection (which corresponds to the hi-bef group of the present study) and the LPS-  39 
only group [31]. However, each dosage of IL-10 was completely administered within 40 
minutes in both studies, thus different kinetics of deposition of IL-10 within the lung do 
not seem the presumable cause. In lungs, IL-10 can be mainly formed from alveolar 
macrophages [72] and as mentioned above, the vital number of alveolar macrophages in 
BAL from the hi-bef group was significantly higher than that from the LPS-only group 
in the present study. We speculate, that this is due to the deposition from nebulised IL-10. 
Moreover, the meaning of the significant elevation of IL-10 concentration in BALF 
from the hi-bef group as compared to the LPS-only group in the present study has been 
not comprehensively understood. It may be speculated that animals of the hi-bef group 
have better outcome than those of the LPS-only group. Donnelly et al. in 1996 reported 
that low IL-10 concentration in BALF from ARDS patients increased significantly the 
mortality rate [17]. 
4.2.5. Cytokine concentrations  in Plasma 
Experimental endotoxemia resulted in significant elevation of TNF-α, IL-1ß, IL-6, and 
IFN-γ cytokine concentrations in plasma [31] [41] [57]. However, IL-10 administered 
before LPS exposure significantly reduced the LPS-induced release of proinflammatory 
cytokines in plasma [19] [41] [57]. IL-10 is known to inhibit the production and release 
of proinflammatory cytokines by affecting both mRNA synthesis and degradation [77].  
In the present study, we found that only the hi-bef group decreased significantly TNF-α, 
IL-1ß, IL-6, and IFN-γ cytokine concentrations in plasma as compared to the LPS-only 
group  (p<  0.0125).  In  contrast,  in  a  previous  study,  we  reported  that  there  was  no 
statistically significant difference in TNF-α concentration in plasma between the group 
of inhalation of 5µg IL-10 before LPS injection (which corresponds to the hi-bef group 
of the present study) and the LPS-only group [31]. Kinetics of TNF-α might be a reason   40 
for different results between our studies. In sepsis, TNF-α, one of the most important 
early inflammatory response cytokines, was released into plasma during the first 30-
90min after LPS exposure [44] and TNF-α level in plasma peaked 90min after LPS 
challenge [28].  
The  decline  of  proinflammatory  cytokine  concentrations  in  plasma  from  the  hi-bef 
group implicates that inhaled IL-10 before LPS injection did not act exclusively within 
the lungs but also in the systemic circulation. A significant part of deposited IL-10 
aerosol  particles  may  have  passed  the  alveolar  capillary  barrier  into  the  circulatory 
system.  It  can  be  hypothesized  that  the  systemic  concentration  of  IL-10  reached  a 
sufficient level following inhalation of 5µg IL-10 before LPS injection to inhibit the 
release  of  endogenously  synthesized  proinflammatory  cytokines  following  LPS 
injection.  
In addition, in the present study, IFN-γ concentrations in plasma from the lo-bef and lo-
aft  groups  were  significantly  lower  than  that from  the  LPS-only  group  (p<  0.0125) 
which is in line with other reports. Marchant et al. in 1994 found that administration of 
IL-10 (1000U) 30min before or 3h after LPS administration (100µg) decreased peak 
IFN-γ serum levels in rats [49]. The influence of IL-10 administration on inflammatory 
reactions  is  different  and  depends  on  the  time  point  of  its  administration;  in  some 
scenarios the expected immunosuppressive activities are observed, while in others IL-10 
enhances immune or inflammatory responses [42] [57]. Lauw et al. in 2000 found that 
IL-10 intravenously injected 1h after LPS injection not only had no suppression of LPS-
induced proinflammatory cytokine release, but also increased significantly IFN-γ level 
in plasma as compared to the placebo group (which corresponds to the LPS-only group 
of the present study) [42]. The difference in IFN-γ levels in plasma between the lo-aft   41 
group in the present study and the group receiving IL-10 after LPS injection in the study 
from Lauw et al. may be explained by different subjects (rats vs. human volunteers), 
doses of LPS injection (5mg/kg vs. 4ng/kg), routes of IL-10 administration (inhalation 
vs. intravenous injection), doses of IL-10 (0.5µg vs. 25µg/kg), and time points of IL-10 
administration (just after LPS injection vs. 1h after LPS injection). However, Lauw et 
al. in 2000 also reported that a stimulation of IFN-γ production was found in whole 
blood cultured with LPS for 24h and the addition of IL-10 resulted in a strong inhibition 
of LPS-induced IFN-γ release. The intensity of inhibition was dependent on dose and 
time points of IL-10 administration  [42].  
In the present study, LPS injection resulted in an elevation not only of proinflammatory 
cytokine concentrations but also of IL-10 concentration in plasma (288(68)pg/ml in the 
LPS-only  group  vs.  29(39)pg/ml  in  the  Sham  group).  Normally,  endogenous 
concentrations of IL-10 in plasma are found below the detectable limit [58]. ARDS and 
sepsis increase the endogenous IL-10 synthesis [43] [59]. Levels of endogenous IL-10 
increased  rapidly  in  endotoxemic  rats  peaking  within  1h  after  LPS  challenge  and 
persisting in plasma for at least 6h [5] [49]. Interleukin-10 may be important for directly 
suppressing late as well as early events leading to endotoxic shock. 
In the present study we found that IL-10 concentration in plasma four hours after LPS 
injection from groups receiving IL-10 aerosol was not significantly different from the 
LPS-only group. Our finding was conformed to other reports which showed that IL-10 
levels in serum did not differ between rats receiving injection of LPS alone as compared 
to  rats  receiving  simultaneous  injection  of  LPS  (12mg/kg)  and  IL-10  (20µg/kg  or 
40µg/kg) [36] or rats receiving IL-10 inhalation (5µg) prior to LPS injection (5mg/kg) 
in experimental models of LPS-induced acute lung injury [31]. A reason for that may be   42 
that local binding and absorption of aerosolized cytokines by resident cells may further 
limit  spilling  over  of  aerosolized  cytokines  into  the  systemic  circulation  [12]  or 
accumulation  of  exogenously  administered  proteins  following  aerosolisation  to  the 
airway. Another possibility may be that administration of exogenous IL-10 may lead to 
negative feed back regulation of endogenous IL-10 synthesis.  
There is evidence that IL-10 concentration in plasma is directly related to the severity of 
inflammation and mortality rate in patients with trauma, sepsis, and ARDS [43] [59] 
[64]. Patients with septic shock presenting high IL-10 levels in plasma had higher organ 
failure scores than those with low IL-10 levels [22]. Moreover, both the IL-10 level in 
serum and the ratio of IL-10 to TNF-α were higher in nonsurvivors during severe sepsis 
[29]. In the present study, IL-10 concentration in plasma from the hi-bef group tended to 
decline as compared to the LPS-only group (161(143)pg/ml vs. 288(68)pg/ml). Thus, it 
may be speculated that the inhalation of 5µg IL-10 before LPS injection improved the 
severity of inflammation in the endotoxemic model. 
Taking into account the decline of proinflammatory cytokine concentrations in plasma 
in the endotoxemic model in the present study, inhalation of 5µg IL-10 before LPS 
injection  may  be  more  beneficial  than  inhalation  of  IL-10  during  experimental 
endotoxemia.  This would also underline the hypothesis of Berg et al. in 1995 who 
suggested that IL-10 must act early in order to block the pathogenic effects of LPS [5]. 
Interleukin-10-mediated protection of mice from lethal endotoxemia was achieved when 
IL-10  was  administered  either  prior  to,  or  concurrently  with  LPS  or  staphylococcal 
enterotoxin B [4] [33].   43 
The present study did not include a group in which IL-10 was nebulised without a 
subsequent injection of LPS, which would allow the evaluation of local and systemic 
effects of nebulised IL-10 itself. This may limit the present study.   44 
4.3. Conclusions 
In summary, only the nebulisation of IL-10 at 5µg (1ml, 5µg/ml, corresponding to 0.19µg/rat) 
before induction of experimental endotoxemia resulted in reduced plasma levels of TNF-α, IL-1ß, 
IL-6, and IFN-γ as well as reduced nitrite release of cultured alveolar macrophages following 4h 
of  experimental  endotoxemia.  In  contrast,  the  inhalation  of  IL-10  at  the  same  dose 
administered subsequently to the induction of experimental endotoxemia had no effect 
on proinflammatory plasma cytokines or nitrite release from alveolar macrophages. 
The inhalation of IL-10 at 0.5µg (1ml, 0.5µg/ml, corresponding to 0.019µg/rat) before or 
following  induction  of  experimental  endotoxemia  did  not  result  in  a  significant 
reduction  of  proinflammatory  plasma  cytokines  or  nitrite  release  from  alveolar 
macrophages. 
IL-10 aerosol at either dose or time point had no significant effects on cytokine levels in 
the bronchoalveolar fluid. 
We conclude, that IL-10 has anti-inflammatory effects on alveolar macrophages and 
plasma cytokines only when it is applied before induction of endotoxemia at 5µg (1ml, 
5µg/ml, corresponding to 0.19µg/rat).  Effects of IL-10 are not bounded to the pulmonary 
compartment, they rather appear systemically. 
   45 
5. SUMMARY 
To determine the effects of inhaled IL-10 at different doses and different time points on 
the pulmonary and systemic inflammatory response during endotoxemia, 48 ventilated, 
anaesthetized rats  (mean body weight ± standard deviation, 500 ± 33g) were randomly 
assigned to six groups (n = 8, each). Interleukin-10 was nebulised either prior to or 
following the intravenous injection of LPS (5mg/kg) at two doses (5.0µg or 0.5µg) in 
four groups. Eight rats received the same insult with no further treatment (LPS-only 
group). Another eight rats served as controls without endotoxemia but with aerosolized 
phosphate-buffered saline, the solvent of IL-10 (Sham group).  
Concentrations  of  TNF-α,  IL-1ß,  IL-6,  and  IFN-γ  were  analyzed  in  plasma  and 
bronchoalveolar  lavage  fluid  (BALF).  In  addition,  the  nitrite  release  from  ex-vivo 
cultured alveolar macrophages was determined.  
As compared to the LPS-only group, the concentrations of the proinflammatory cytokines 
TNF-α, IL-1ß, IL-6, and IFN-γ in plasma were significantly reduced in the group, which 
inhaled 5µg IL-10 before LPS injection (p< 0.0125). Spontaneous nitrite release from ex-
vivo cultured alveolar macrophages was suppressed in this group (p< 0.0125).  
Inhalation of 0.5µg IL-10 before LPS injection and both dosages of IL-10 inhalation 
(5µg or 0.5µg) after LPS injection did not significantly influence either inflammatory 
cytokine concentrations in BALF, in plasma or the nitrite release from ex-vivo cultured 
alveolar macrophages. 
In this study, inhaled IL-10 only demonstrated anti-inflammatory effects when it was 
administered at 5µg prior to the induction of experimental endotoxemia. Interleukin-10 
aerosol had no effect when it was given either following induction of endotoxemia or   46 
given at a lower dosage (which here was 0.5µg) either before or following injection of 
lipopolysaccharide.    47 
ZUSAMMENFASSUNG 
Das  „Acute  Respiratory  Distress  Syndrome“  (ARDS)  ist  eine  akut  auftretende, 
überwiegend  Sepsis-induzierte,  inflammatorische  Erkrankung  der  Lunge  mit  hoher 
Letalität. Ein komplexes Netzwerk aus Zytokinen und anderen proinflammatorischen 
Mediatoren unterhält die pulmonale Entzündungreaktion. Dem Zytokin Interleukin-10 
(IL-10)  könnte  in  diesem  Zusammenhang  aufgrund  seines  spezifisch 
antiinflammatorischen  und  immunmodulierenden  Wirkspektrums  eine  therapeutische 
Bedeutung zukommen. In tierexperimentellen Untersuchungen konnten die protektiven 
Wirkungen  von  systemisch  appliziertem  Interleukin-10  bezüglich  verringerter 
Wirkspiegel proinflammatorischer Mediatoren sowie des Überlebens der Versuchstiere 
bei  Sepsis  belegt  werden.  In  einer  Untersuchung  an  ARDS-Erkrankten  wiesen 
Patienten, deren bronchoalveoläre Lavage (BAL) hohe Konzentrationen an Interleukin-
10 enthielt, eine signifikant niedrigere Letalität auf als Patienten mit niedriger IL-10 
Konzentration. 
Die Inhalation von IL-10 über den Luftweg könnte lokal in der Lunge die Freisetzung 
von  Entzündungsmediatoren  verringern  und  so  den  Verlauf  eines  ARDS  positiv 
beeinflussen.  
Im  Rahmen  einer  bereits  durchgeführten  Studie  der  eigenen  Arbeitsgruppe  konnte 
gezeigt  werden,  dass  die  Inhalation  von  IL-10  (0.19µg/Tier)  vor  Induktion  einer 
experimentellen  Endotoxinämie  (Beobachtungszeitraum  6h)  zur  signifikanten 
Reduktion proinflammatorischer Zytokine im Plasma sowie der BAL führte. Daneben 
bewirkte IL-10 Aerosol eine signifikante Verringerung der Nitritproduktion aus ex vivo 
kultivierten Alveolarmakrophagen (AM).   48 
Mit der  vorliegenden  Studie  sollte untersucht werden, ob vernebeltes  IL-10  auch in 
einer  geringeren  Dosierung  als  in  der  ersten  Studie  angewandt  antiinflammatorisch 
wirksam ist. Daneben sollte geklärt werden, ob der Zeitpunkt der Applikation des IL-10 
Aerosol relevant ist. Konkret sollte untersucht werden, ob die Inhalation von IL-10 erst 
nach  Induktion  der  experimentellen  Endotoxinämie  ebenfalls  antinflammatorisches 
Potential besitzt. 
Die  Generierung  und  Verneblung  des  IL-10  Aerosols  erfolgte  in  der  vorliegenden 
Untersuchung mittels eines speziell für diesen Einsatz von der eigenen Arbeitsgruppe 
entwickelten und charakterisierten Verneblersystems. Der Vernebler produziert stabil 
Aerosopartikel, deren Größenverteilung (rund 2µm) mit hoher Wahrscheinlichkeit in 
alvelären Bereichen deponiert. Die alveoläre Depositionsfraktion des Verneblers beträgt 
rund  4%  und  liegt  damit  in  einem  Bereich,  der  aus  der  Humanmedizin  für  die 
Verneblung bei intubierten Patienten bekannt ist. 
An  48  narkotisierten,  kontrolliert  beatmeten  Ratten  wurde  die  antiinflammatorische 
Wirkung  eines  IL-10-Aerosols  untersucht.  Die  Induktion  des  experimentellen 
Lungenschadens  erfolgte  durch  intravenöse  Injektion  von  Endotoxin 
(Lipopolysaccharid; LPS, in einer Dosierung von 5mg/kg). Als löslicher Bestandteil der 
Membran  gram-negativer  Bakterien  führt  LPS  über  die  Freisetzung 
proinflammatorischer  Substanzen  zu  entzündlichen  Reaktionen,  die  lokal  beschränkt 
oder auch systemisch auftreten können. Bei Versuchstieren unterschiedlicher Spezies 
bewirkt die systemische Applikation von LPS pulmonale Veränderungen, die denen des 
septisch  bedingten  ARDS  des  Menschen  qualitativ  entsprechen.  Die  Tiere  wurden 
zufällig in eine der sechs Versuchsgruppen eingeteilt (je n=8): Die LPS-Gruppe erhielt 
eine LPS-Injektion (5 mg/kg/KG) ohne anschließende therapeutische Intervention.    49 
Die mit IL-10 behandelten Tiere erhielten das IL-10-Aerosol entweder vor oder nach 
Induktion der experimentellen Endotoxinämie nach unten genanntem Protokoll. In einer 
Kontroll  (Sham)-Gruppe  wurde  die  Auswirkung  von  Narkose,  chirurgischer 
Präparation,  Beatmung  und  Aerosolapplikation  (IL-10-Trägerlösung; 
phosphatgepufferte  Kochsalzlösung)  evaluiert.  Neben  der  in  vivo  Beobachtung  von 
Hämodynamik  (Herzfrequenz,  mittlerer  arterieller  Blutdruck),  Lungenmechanik, 
arteriellen Blutgasen und Blutbild, untersuchten wir anhand von Blutproben und einer 
Bronchoalveolären  Lavage  (BAL)  die  systemische  und  pulmonale  Inflammation 
(inflammatorische Zytokine TNFα, IL-1ß, IL-6 und IFNγ in Plasma und BAL). 
Die Verneblung von IL-10 erfolgte in zwei Dosierungen und zu zwei Zeitpunkten: in 
einer Gruppe wurde IL-10 in einer Dosierung von 5.0µg (0.19µg/Tier) vor, und in einer 
weiteren Gruppe nach Induktion der experimentellen Endotoxinämie vernebelt. In zwei 
weiteren Versuchgruppen wurde IL-10 in einer Dosierung von 0.5µg (0.019µg/Tier) 
ebenfalls vor sowie nach Injektion von LPS vernebelt. 
Die  Endotoxinämie  führte  nur  zu  geringen  Verschlechterungen  der  klinischen 
Parameter, aber sowohl pulmonal (BAL) als auch systemisch (Plasma) zeigte sich ein 
Anstieg proinflammatorischer Mediatoren. Gegenüber den Tieren, deren Endotoxinämie 
unbehandelt blieb, bewirkte nur die Inhalation von IL-10 in der höheren Dosierung (5µg) 
das  signifikante  Abfallen  der  proinflammatorischen  Zytokine  TNFα,  IL-1ß,  IL-6  und 
IFNγ im Plasma sowie der Freisetzung von Nitrit aus kultivierten AM. IL-10 Aerosol 
hatte  in  keiner  Dosierung  respektive  zu  keinem  Applikationszeitpunkt 
antiinflammatorische Effekte auf die Zytokinkonzentrationen in der BAL.  
Die präemptive Vernebelung von IL-10 in einer Dosierung von 5 µg (0.19µg/Tier) vor 
Induktion einer experimentellen Endotoxinämie zeigte sowohl auf die AM Kultur als   50 
auch systemisch (Plasma) antinflammatorisches Wirkprofil. Demgegenüber zeigte IL-10 
keine antinflammatorische Effekte, wenn es erst nach Injektion von LPS oder aber in 
geringerer Dosierung vernebelt wurde.  
Zur  antiinflammatorischen  Therapie  der  experimentellen  Endotoxinämie  durch  LPS 
Injektion  in  der  Spezies  Ratte  erscheint  IL-10  Aerosol  nur  wirksam,  wenn  es  in 
ausreichender Dosierung (5 µg) sowie vor Injektion von LPS appliziert wird.   51 
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